|
|
• Rob Weyant, Centers for Disease Control and Prevention—Synthetic DNA and the Select Agent Regulations.
|
|
• Claudia Mickelson, Massachusetts Institute of Technology—IBC, RAC guidelines and concerns about sequences.
|
|
• Edward You, Federal Bureau of Investigation—Surveillance of Select Agent list and emerging concerns.
|
|
• Amy Patterson, National Institutes of Health, Office of Biotechnology Activities—Comprehensive view and the need for this study.
|
|
Panel discussion: ~30 min
|
|
10:30 a.m.
|
Break
|
|
10:45 a.m.
|
Session 2: Current Mechanisms and Criteria for Screening and Surveillance
|
|
What is currently being done? How are sequences chosen to monitor? What is a “sequence of concern”?
|
|
*Moderator—John Mulligan
|
|
• Pete Pesenti, Department of Homeland Security—What are the factors and process used for risk assessment? What are the criteria or characteristics of agents (or sequences) considered a threat?
|
|
• John Mulligan, Blue Heron Biotechnology—What are the current screening practices, standards, and procedures in the industry? What are challenges and concerns?
|
|
• Marcus Graf, GeneArt and Claes Gustafsson, DNA 2.0—Representing companies working to harmonize screening techniques. What would they like to know to help the decision making process?
|
|
• Stephen M. Maurer, University of California at Berkeley—Interface of biosecurity, synthetic biology, and industry.
|
|
Panel discussion: ~30 min ** Ed You, FBI will join panel **
|
